D'Haens G - Search Results

1

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial.

Vermeire S, D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV, Bhatia S, Agboton C, Rosario M, Chen C, Zhang W, Kisfalvi K, Sandborn WJ. Vermeire S, et al. J Crohns Colitis. 2022 Jan 28;16(1):27-38. doi: 10.1093/ecco-jcc/jjab133. J Crohns Colitis. 2022. PMID: 34402887 Free PMC article. Clinical Trial.

2

Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study.

D'Haens G, Geboes K, Peeters M, Baert F, Ectors N, Rutgeerts P. D'Haens G, et al. Am J Gastroenterol. 1997 Aug;92(8):1275-9. Am J Gastroenterol. 1997. PMID: 9260788

3

Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum.

D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. D'Haens GR, et al. Gastroenterology. 1998 Feb;114(2):262-7. doi: 10.1016/s0016-5085(98)70476-7. Gastroenterology. 1998. PMID: 9453485

4

Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease.

D'Haens G, Verstraete A, Cheyns K, Aerden I, Bouillon R, Rutgeerts P. D'Haens G, et al. Aliment Pharmacol Ther. 1998 May;12(5):419-24. doi: 10.1046/j.1365-2036.1998.00321.x. Aliment Pharmacol Ther. 1998. PMID: 9663720 Free article. Clinical Trial.

5

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ. Baert FJ, et al. Gastroenterology. 1999 Jan;116(1):22-8. doi: 10.1016/s0016-5085(99)70224-6. Gastroenterology. 1999. PMID: 9869598 Clinical Trial.

6

Methotrexate in refractory Crohn's disease.

Vandeputte L, D'Haens G, Baert F, Rutgeerts P. Vandeputte L, et al. Inflamm Bowel Dis. 1999 Feb;5(1):11-5. doi: 10.1097/00054725-199902000-00002. Inflamm Bowel Dis. 1999. PMID: 10028444

7

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.

D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P. D'haens G, et al. Gastroenterology. 1999 May;116(5):1029-34. doi: 10.1016/s0016-5085(99)70005-3. Gastroenterology. 1999. PMID: 10220494 Clinical Trial.

8

Acute lower gastrointestinal bleeding in Crohn's disease: characteristics of a unique series of 34 patients. Belgian IBD Research Group.

Belaiche J, Louis E, D'Haens G, Cabooter M, Naegels S, De Vos M, Fontaine F, Schurmans P, Baert F, De Reuck M, Fiasse R, Holvoet J, Schmit A, Van Outryve M. Belaiche J, et al. Am J Gastroenterol. 1999 Aug;94(8):2177-81. doi: 10.1111/j.1572-0241.1999.01291.x. Am J Gastroenterol. 1999. PMID: 10445546

9

Lymphocytic colitis: a distinct clinical entity? A clinicopathological confrontation of lymphocytic and collagenous colitis.

Baert F, Wouters K, D'Haens G, Hoang P, Naegels S, D'Heygere F, Holvoet J, Louis E, Devos M, Geboes K. Baert F, et al. Gut. 1999 Sep;45(3):375-81. doi: 10.1136/gut.45.3.375. Gut. 1999. PMID: 10446105 Free PMC article.

10

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Rutgeerts P, et al. Gastroenterology. 1999 Oct;117(4):761-9. doi: 10.1016/s0016-5085(99)70332-x. Gastroenterology. 1999. PMID: 10500056 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

603 results

Search Page